Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

Figure 6

Observed and model-fitted tumor growth curves in an A431 carcinoma xenograft model. (A) Mice with established A431 tumors received PBS (purple line), human IgG2 500 μg (blue line), panitumumab 5 μg (orange line), 20 μg (brown line), 200 μg (red line) or 500 μg (green line) for 52 days. Mice were monitored continuously for 300 days after the last dose of panitumumab was administered. (B) Tumor inhibition modeled data.

Back to article page

Molecular Cancer

ISSN: 1476-4598